Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

In vitro and in vivo evaluation of Bacillus amyloliquefaciens E35 as prophylactic agents against Singapore grouper iridovirus.

  • 2026-07
  • Fish & shellfish immunology 174

Study Design

Type
Clinical Trial
Population
Trachinotus ovatus
Methods
evaluated the anti-SGIV activity of E35 and extracts in vivo and in vitro; dietary supplementation with live E35 in T. ovatus
As the main highly pathogenic pathogen of grouper, Singapore grouper iridovirus (SGIV) can give rise to significant economic losses in grouper aquaculture. Bacillus amyloliquefaciens, is a probiotic with proven positive effects on grouper and Trachinotus ovatus, protecting those species against several bacterial pathogens. However, its antiviral activity remains to be investigated. We have previously isolated B. amyloliquefaciens E35, a probiotic with a desirable effect on pathogenic bacteria. We aimed to evaluate the anti-SGIV activity of E35 and extracts in vivo and in vitro, and the current study is a step forward in the use of probiotics against viral infections. The results showed that E35 extracts had concentration dependent antiviral effects against SGIV in vitro. It could limit SGIV infection by interacting with SGIV virus particles, interfering with the adsorption, invasion and replication process of SGIV infection. Furthermore, dietary supplementation with live E35 in T. ovatus led to significantly lower viral loads in liver, spleen, and head kidney, and reduced cumulative mortality, highlighting its potential to enhance host resistance against SGIV challenge. Collectively, these findings demonstrate that E35-supplemented feeding can be a promising prophylactic strategy against SGIV and provide a theoretical basis for the development of anti-SGIV drugs in aquaculture.

Research Insights

Back to top